PDMR Shareholding

RNS Number : 3448O

Faron Pharmaceuticals Oy

16 May 2018

 

Faron Pharmaceuticals Oy

("Faron" or the "Company")

  PDMR Dealing

TURKU - FINLAND, 16 May 2018 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, announces that on 16 May 2018 it was notified that on 15 May 2018 Dr Jonathan Knowles, a Non-Executive Director of Faron has acquired 7,200 ordinary shares in Faron at an average price of 118.00 pence per ordinary share and 1,300 ordinary shares in Faron at an average price of 116.97 pence per ordinary share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Jonathan Knowles
2	Reason for notification
a.	Position/Status	Person discharging managerial responsibilities Non-Executive Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Oy
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			118.00 GBPp 116.97 GBPp	7,200 1,300
d.	Aggregated information - Aggregated Volume - Price	8,500 GBP 10,016.61
e.	Date of the transaction	May 15, 2018
f.	Place of the transaction	Turku

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer
[e-mail]

Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey Neville
Phone: [phone]
E-mail: [e-mail]

Westwicke Partners, IR (US)
Chris Brinzey
Phone: [phone]
E-Mail: [e-mail]

Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: [phone]

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome ("ARDS"). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a ground breaking preclinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

 

END

 

 

DSHSFEFMMFASEII